Skip to main content

Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.

Publication ,  Journal Article
Sun, K; Eudy, AM; Harris, N; Pisetsky, DS; Criscione-Schreiber, LG; Sadun, RE; Doss, J; Clowse, MEB; Rogers, JL
Published in: J Patient Rep Outcomes
December 21, 2023

OBJECTIVE: To account for heterogeneity in systemic lupus erythematosus (SLE) and bridge discrepancies between patient- and physician-perceived SLE activity, we developed the Type 1 and 2 SLE model. We examined PROMIS-29 scores, a composite patient-reported outcome (PRO) measure, through the lens of the model. METHODS: Patients completed PROMIS-29 and the polysymptomatic distress scale (PSD). Rheumatologists completed the SLE disease activity index (SLEDAI), and physician's global assessments (PGAs) for Type 1 and 2 SLE. We defined Type 1 SLE using SLEDAI, Type 1 PGA, and active nephritis, and Type 2 SLE using PSD and Type 2 PGA. We compared PROMIS-29 T-scores among Type 1 and 2 SLE groups and explored whether PROMIS-29 can predict Type 1 and 2 SLE activity. RESULTS: Compared to the general population, patients with isolated Type 1 SLE reported greater pain and physical dysfunction but less depression and improved social functions; patients with high Type 2 SLE (irrespective of Type 1 activity) reported high levels of pain, fatigue, and social and physical limitations. Patients with minimal Type 1 and 2 SLE had less depression and greater physical functioning with other domains similar to national norms. PROMIS-29 predicted Type 2 but not Type 1 SLE activity. CONCLUSION: PROMIS-29 similarities in patients with high Type 2 SLE, with and without active Type 1 SLE, demonstrate the challenges of using PROs to assess SLE inflammation. In conjunction with the Type 1 and 2 SLE model, however, PROMIS-29 identified distinct symptom patterns, suggesting that the model may help clinicians interpret PROs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Patient Rep Outcomes

DOI

EISSN

2509-8020

Publication Date

December 21, 2023

Volume

7

Issue

1

Start / End Page

136

Location

Germany

Related Subject Headings

  • Symptom Burden
  • Pain
  • Nephritis
  • Lupus Erythematosus, Systemic
  • Humans
  • Cross-Sectional Studies
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sun, K., Eudy, A. M., Harris, N., Pisetsky, D. S., Criscione-Schreiber, L. G., Sadun, R. E., … Rogers, J. L. (2023). Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study. J Patient Rep Outcomes, 7(1), 136. https://doi.org/10.1186/s41687-023-00678-5
Sun, Kai, Amanda M. Eudy, Nathaniel Harris, David S. Pisetsky, Lisa G. Criscione-Schreiber, Rebecca E. Sadun, Jayanth Doss, Megan E. B. Clowse, and Jennifer L. Rogers. “Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.J Patient Rep Outcomes 7, no. 1 (December 21, 2023): 136. https://doi.org/10.1186/s41687-023-00678-5.
Sun K, Eudy AM, Harris N, Pisetsky DS, Criscione-Schreiber LG, Sadun RE, et al. Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study. J Patient Rep Outcomes. 2023 Dec 21;7(1):136.
Sun, Kai, et al. “Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.J Patient Rep Outcomes, vol. 7, no. 1, Dec. 2023, p. 136. Pubmed, doi:10.1186/s41687-023-00678-5.
Sun K, Eudy AM, Harris N, Pisetsky DS, Criscione-Schreiber LG, Sadun RE, Doss J, Clowse MEB, Rogers JL. Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study. J Patient Rep Outcomes. 2023 Dec 21;7(1):136.

Published In

J Patient Rep Outcomes

DOI

EISSN

2509-8020

Publication Date

December 21, 2023

Volume

7

Issue

1

Start / End Page

136

Location

Germany

Related Subject Headings

  • Symptom Burden
  • Pain
  • Nephritis
  • Lupus Erythematosus, Systemic
  • Humans
  • Cross-Sectional Studies
  • 42 Health sciences
  • 32 Biomedical and clinical sciences